Effects of sporadic inclusion body myositis on skeletal muscle fibre type specific morphology and markers of regeneration and inflammation
Tóm tắt
Sporadic inclusion body myositis (sIBM) is a subgroup of idiopathic inflammatory myopathies characterised by progressive muscle weakness and skeletal muscle inflammation. Quantitative data on the myofibre morphology in sIBM remains scarce. Further, no previous study has examined fibre type association of satellite cells (SC), myonuclei number, macrophages, capillaries, and myonuclear domain (MD) in sIBM patients. Muscle biopsies from sIBM patients (n = 18) obtained previously (NCT02317094) were included in the analysis for fibre type-specific myofibre cross-sectional area (mCSA), SCs, myonuclei and macrophages, myonuclear domain, and capillarisation. mCSA (p < 0.001), peripheral myonuclei (p < 0.001) and MD (p = 0.005) were higher in association with type 1 (slow-twitch) than type 2 (fast-twitch) fibres. Conversely, quiescent SCs (p < 0.001), centrally placed myonuclei (p = 0.03), M1 macrophages (p < 0.002), M2 macrophages (p = 0.013) and capillaries (p < 0.001) were higher at type 2 fibres compared to type 1 fibres. In contrast, proliferating (Pax7+/Ki67+) SCs (p = 0.68) were similarly associated with each fibre type. Type 2 myofibres of late-phase sIBM patients showed marked signs of muscle atrophy (i.e. reduced mCSA) accompanied by higher numbers of associated quiescent SCs, centrally placed myonuclei, macrophages and capillaries compared to type 1 fibres. In contrast, type 1 fibres were suffering from pathological enlargement with larger MDs as well as fewer nuclei and capillaries per area when compared with type 2 fibres. More research is needed to examine to which extent different therapeutic interventions including targeted exercise might alleviate these fibre type-specific characteristics and countermeasure their consequences in impaired functional performance.
Từ khóa
Tài liệu tham khảo
Greenberg SA (2019) Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 15(5):257–272. https://doi.org/10.1038/s41584-019-0186-x
Naddaf E, Barohn RJ, Dimachkie MM (2018) Inclusion body myositis: update on pathogenesis and treatment. Neurotherapeutics 15(4):995–1005. https://doi.org/10.1007/s13311-018-0658-8
Yunis EJ, Samaha FJ (1971) Inclusion body myositis. Lab Invest 25(3):240–248
Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP (1995) Inclusion body myositis and myopathies. Ann Neurol 38(5):705–713. https://doi.org/10.1002/ana.410380504
Karpati G, O’Ferrall EK (2009) Sporadic inclusion body myositis: pathogenic considerations. Ann Neurol 65(1):7–11. https://doi.org/10.1002/ana.21622
Askanas V, Engel WK (2008) Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains. Acta Neuropathol 116(6):583–595. https://doi.org/10.1007/s00401-008-0449-0
Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J, Kampen RL, Bruno DA, Kirk AD (2009) Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132(Pt 6):1536–1544. https://doi.org/10.1093/brain/awp104
Hou Y, Luo YB, Dai T, Shao K, Li W, Zhao Y, Lu JQ, Yan C (2018) Revisiting pathological classification criteria for adult idiopathic inflammatory myopathies: in-depth analysis of muscle biopsies and correlation between pathological diagnosis and clinical manifestations. J Neuropathol Exp Neurol 77(5):395–404. https://doi.org/10.1093/jnen/nly017
de Camargo LV, de Carvalho MS, Shinjo SK, de Oliveira ASB, Zanoteli E (2018) Clinical, histological, and immunohistochemical findings in inclusion body myositis. Biomed Res Int 2018:5069042. https://doi.org/10.1155/2018/5069042
Jensen KY, Jacobsen M, Schrøder HD, Aagaard P, Nielsen JL, Jørgensen AN, Boyle E, Bech RD, Rosmark S, Diederichsen LP, Frandsen U (2019) The immune system in sporadic inclusion body myositis patients is not compromised by blood-flow restricted exercise training. Arthritis Res Ther 21(1):293. https://doi.org/10.1186/s13075-019-2036-2
Muth IE, Barthel K, Bähr M, Dalakas MC, Schmidt J (2009) Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry 80(12):1344–1349. https://doi.org/10.1136/jnnp.2009.174276
Arnardottir S, Alexanderson H, Lundberg IE, Borg K (2003) Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 35(1):31–35. https://doi.org/10.1080/16501970306110
Arnardottir S, Borg K, Ansved T (2004) Sporadic inclusion body myositis: morphology, regeneration, and cytoskeletal structure of muscle fibres. J Neurol Neurosurg Psychiatry 75(6):917–920. https://doi.org/10.1136/jnnp.2003.018994
Tajsharghi H, Thornell LE, Darin N, Martinsson T, Kyllerman M, Wahlström J, Oldfors A (2002) Myosin heavy chain IIa gene mutation E706K is pathogenic and its expression increases with age. Neurology 58(5):780–786. https://doi.org/10.1212/wnl.58.5.780
Jørgensen AN, Aagaard P, Frandsen U, Boyle E, Diederichsen LP (2018) Blood-flow restricted resistance training in patients with sporadic inclusion body myositis: a randomized controlled trial. Scand J Rheumatol 47(5):400–409. https://doi.org/10.1080/03009742.2017.1423109
Team R (2022) RStudio: Integrated Development Environment for R. In., Boston, MA
Larsson L, Sjödin B, Karlsson J (1978) Histochemical and biochemical changes in human skeletal muscle with age in sedentary males, age 22–65 years. Acta Physiol Scand 103(1):31–39. https://doi.org/10.1111/j.1748-1716.1978.tb06187.x
Frontera WR, Hughes VA, Fielding RA, Fiatarone MA, Evans WJ, Roubenoff R (2000) Aging of skeletal muscle: a 12-yr longitudinal study. J Appl Physiol (Bethesda, Md: 1985) 88(4):1321–1326. https://doi.org/10.1152/jappl.2000.88.4.1321
Mattiello-Sverzut AC, Chimelli L, Moura MS, Teixeira S, de Oliveira JA (2003) The effects of aging on biceps brachii muscle fibers: a morphometrical study from biopsies and autopsies. Arq Neuropsiquiatr 61(3a):555–560. https://doi.org/10.1590/s0004-282x2003000400006
Nederveen JP, Joanisse S, Snijders T, Ivankovic V, Baker SK, Phillips SM, Parise G (2016) Skeletal muscle satellite cells are located at a closer proximity to capillaries in healthy young compared with older men. J Cachexia Sarcopenia Muscle 7(5):547–554. https://doi.org/10.1002/jcsm.12105
Andersen LL, Suetta C, Andersen JL, Kjær M, Sjøgaard G (2008) Increased proportion of megafibers in chronically painful muscles. Pain 139(3):588–593. https://doi.org/10.1016/j.pain.2008.06.013
Karlsen A, Couppé C, Andersen JL, Mikkelsen UR, Nielsen RH, Magnusson SP, Kjaer M, Mackey AL (2015) Matters of fiber size and myonuclear domain: does size matter more than age? Muscle Nerve 52(6):1040–1046. https://doi.org/10.1002/mus.24669
Tøien T, Nielsen JL, Berg OK, Brobakken MF, Nyberg SK, Espedal L, Malmo T, Frandsen U, Aagaard P, Wang E (2023) The impact of life-long strength versus endurance training on muscle fiber morphology and phenotype composition in older men. J Appl Physiol (Bethesda, Md:1985) 135(6):1360–1371. https://doi.org/10.1152/japplphysiol.00208.2023
Nelke C, Schroeter CB, Theissen L, Preusse C, Pawlitzki M, Räuber S, Dobelmann V, Cengiz D, Kleefeld F, Roos A, Schoser B, Brunn A, Neuen-Jacob E, Zschüntzsch J, Meuth SG, Stenzel W, Ruck T (2023) Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis. Acta Neuropathol 146(5):725–745. https://doi.org/10.1007/s00401-023-02637-2
Horwath O, Envall H, Röja J, Emanuelsson EB, Sanz G, Ekblom B, Apró W, Moberg M (2021) Variability in vastus lateralis fiber type distribution, fiber size, and myonuclear content along and between the legs. J Appl Physiol (Bethesda, Md:1985) 131(1):158–173. https://doi.org/10.1152/japplphysiol.00053.2021
Mackey AL, Andersen LL, Frandsen U, Suetta C, Sjøgaard G (2010) Distribution of myogenic progenitor cells and myonuclei is altered in women with vs those without chronically painful trapezius muscle. J Appl Physiol (Bethesda, Md:1985) 109(6):1920–1929. https://doi.org/10.1152/japplphysiol.00789.2010
Kwon B, Kumar P, Lee HK, Zeng L, Walsh K, Fu Q, Barakat A, Querfurth HW (2014) Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis. Hum Mol Genet 23(14):3681–3694. https://doi.org/10.1093/hmg/ddu077
Morosetti R, Broccolini A, Sancricca C, Gliubizzi C, Gidaro T, Tonali PA, Ricci E, Mirabella M (2010) Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol Aging 31(7):1205–1214. https://doi.org/10.1016/j.neurobiolaging.2008.08.011
Gandolfi S, Pileyre B, Drouot L, Dubus I, Auquit-Auckbur I, Martinet J (2023) Stromal vascular fraction in the treatment of myositis. Cell Death Discov 9(1):346. https://doi.org/10.1038/s41420-023-01605-9
Khuu S, Fernandez JW, Handsfield GG (2023) Delayed skeletal muscle repair following inflammatory damage in simulated agent-based models of muscle regeneration. PLoS Comput Biol 19(4):e1011042. https://doi.org/10.1371/journal.pcbi.1011042
Groen BB, Hamer HM, Snijders T, van Kranenburg J, Frijns D, Vink H, van Loon LJ (2014) Skeletal muscle capillary density and microvascular function are compromised with aging and type 2 diabetes. J Appl Physiol (Bethesda, Md:1985) 116(8):998–1005. https://doi.org/10.1152/japplphysiol.00919.2013
Dahlbom K, Geijer M, Oldfors A, Lindberg C (2019) Association between muscle strength, histopathology, and magnetic resonance imaging in sporadic inclusion body myositis. Acta Neurol Scand 139(2):177–182. https://doi.org/10.1111/ane.13040
Michelle EH, Pinal-Fernandez I, Casal-Dominguez M, Albayda J, Paik JJ, Tiniakou E, Adler B, Mecoli CA, Danoff SK, Christopher-Stine L, Mammen AL, Lloyd TE (2023) Clinical subgroups and factors associated with progression in patients with inclusion body myositis. Neurology 100(13):e1406–e1417. https://doi.org/10.1212/wnl.0000000000206777